Domainex ranked as the fastest growing drug discovery CRO in Europe

CAMBRIDGE, UK - Apr 30, 2018 - Domainex Ltd, a privately-owned drug discovery services company, is proud to announce its inclusion in the second annual top 1000 list of Europes fastest growing companies, published by the Financial Times. The FT 1000 lists the companies, from 31 European countries and across all sectors, that have achieved the highest compound annual growth rate in their revenue between 2013 and 2016. Domainex is the only integrated drug discovery contract research organisation (CRO) to feature on this acclaimed list.

We are delighted to appear in the 2018 FT 1000 listing: our growth over the last 3 years has been achieved entirely organically, comments Tom Mander, COO for Domainex. This reflects our sustained efforts to provide innovative and high quality services to an increasing number of customers including pharmaceutical, biotechnology and academic organisations from around the world. This achievement has only been possible thanks to the hard work and dedication of our staff, over 70% of whom are PhD qualified. Their commitment enables us to deliver value-generating results for our clients in their quest for optimised drug candidates that will ultimately improve the lives of patients. I would like to thank each and every one of them, our investors and of course all of our loyal and valued customers, for their continued support.

Domainex offers drug discovery services that stretch from protein production and assay development, through to medicinal chemistry for lead optimisation. Reflecting its commercial success and ambitious growth strategy, in the last 18 months alone the company has made a number of strategic appointments and expanded its team of international scientists at its research facilities at Chesterford Research Park near Cambridge, UK, by more than 50%. It has also made key investments in technology: for example, it is the only CRO in the UK to offer fragment-based drug discovery using MicroScale Thermophoresis, and the company was recently awarded more than £100,000 by Innovate UK (the UKs innovation agency) to develop a disruptive new screening technology for GPCRs.

Our aim is to significantly increase the speed from drug target to candidate molecule for our clients, adds Trevor Perrior, CSO for Domainex. We are proud of our track record of delivery on their behalf. Domainex has come a long way since it was established in 2001 and we are looking ahead with even greater ambition.

Ends

For more information contact:

Domainex
Dr Tom Mander
T: +44 (0)7584 578024
E: tom.mander@domainex.co.uk

Media Relations - Sciad Communications
Deborah Cockerill / Emma Pickup / Juliette Craggs
T: +44(0)20 7470 8801
E: domainex@sciad.com

Notes to Editors

About Domainex

Established in 2001 as a spin-out from University College London, Birkbeck College, and the Institute of Cancer Research, Domainex Ltd. is a Cambridge-based, privately-owned company that provides integrated medicines research services to global pharmaceutical, biotechnology and academic partners. Its services cover a wide span of the drug research value chain, from disease target selection to pre-clinical candidate nomination. Domainex's services include recombinant protein expression and use of its proprietary technology platform, Combinatorial Domain Hunting to identify soluble protein fragments for structural biology and assay development. Hit finding activities encompass assay development and screening utilising its BioassayBuilder, FragmentBuilder and LeadBuilder platforms. The core of the service offering is undertaking multi-parameter medicinal chemistry optimisation of hits and leads with its every compound counts approach, which can save up to 30% on the average industry time from target to candidate.